Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.
Followers of Nordic Nanovector and Oxford Biomedica, among others, will pay close attention to an early focus of yesterday’s deal.
With data from a head-to-head trial against Cosentyx due soon, UCB’s bimekizumab seeks to enter a crowded psoriasis market.
Abbvie pays handsomely to join the CD20 bispecific brawl, handing over $750m to Genmab for access to a project that trails the competition.
Aduro finally runs up the white flag on Sting agonism, and becomes a listed shell for Chinook Therapeutics.
Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
June will be hectic for the US regulator, with many approval decisions due, including one for subcutaneous Arzerra in multiple sclerosis and Tazverik in follicular…
Filgotinib’s mixed efficacy in ulcerative colitis prompts a shares slide.
Johnson & Johnson is easily the largest big pharma employer, and on certain metrics outstrips smaller rivals.